Insider Selling: uniQure (NASDAQ:QURE) CEO Sells 28,341 Shares of Stock

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 28,341 shares of uniQure stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the transaction, the chief executive officer now directly owns 651,454 shares in the company, valued at $6,703,461.66. This trade represents a 4.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

uniQure Stock Performance

Shares of QURE traded up $0.76 during trading hours on Wednesday, reaching $12.09. 1,028,349 shares of the company’s stock traded hands, compared to its average volume of 1,042,863. The business’s fifty day simple moving average is $14.80 and its two-hundred day simple moving average is $9.89. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The firm has a market capitalization of $589.30 million, a price-to-earnings ratio of -2.44 and a beta of 0.38. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently modified their holdings of the stock. Atria Investments Inc acquired a new stake in uniQure during the 3rd quarter worth about $53,000. Privium Fund Management B.V. raised its position in shares of uniQure by 16.3% in the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after purchasing an additional 104,500 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in uniQure during the third quarter valued at about $69,000. Charles Schwab Investment Management Inc. grew its holdings in uniQure by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock valued at $1,367,000 after buying an additional 16,464 shares during the last quarter. Finally, FMR LLC raised its stake in uniQure by 8,056.6% during the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Leerink Partners lifted their target price on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Wells Fargo & Company cut their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a report on Friday, February 28th. The Goldman Sachs Group lifted their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 price target on shares of uniQure in a research note on Tuesday, January 21st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, uniQure has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.